{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:10:46Z","timestamp":1762409446198,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["7691"],"award-info":[{"award-number":["7691"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00277-018-3392-8","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T22:29:31Z","timestamp":1529533771000},"page":"1919-1924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia"],"prefix":"10.1007","volume":"97","author":[{"given":"Sezaneh","family":"Haghpanah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Eshghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omidreza","family":"Zekavat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Bordbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Hoormand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-1001","authenticated-orcid":false,"given":"Mehran","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"issue":"11","key":"3392_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1056\/NEJMra050436","volume":"353","author":"D Rund","year":"2005","unstructured":"Rund D, Rachmilewitz E (2005) \u03b2-Thalassemia. New Engl J Med 353(11):1135\u20131146","journal-title":"New Engl J Med"},{"key":"3392_CR2","first-page":"090076","volume":"2013","author":"SS Franco","year":"2013","unstructured":"Franco SS, De Falco L, Ghaffari S, Brugnara C, Sinclair DA, Matt\u00e8 A, Iolascon A, Mohandas N, Bertoldi M, An X (2013) Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica:Haematol 2013:090076","journal-title":"Haematologica:Haematol"},{"issue":"D1","key":"3392_CR3","doi-asserted-by":"publisher","first-page":"D1063","DOI":"10.1093\/nar\/gkt911","volume":"42","author":"B Giardine","year":"2014","unstructured":"Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, Bartsakoulia M, Riemer C, Miller W, Tzimas G (2014) Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 42(D1):D1063\u2013D1069","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3392_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-5-11","volume":"5","author":"R Galanello","year":"2010","unstructured":"Galanello R, Origa R (2010) Beta-thalassemia. Orphanet J Rare Dis 5(1):11","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3392_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","volume":"12","author":"A Cao","year":"2010","unstructured":"Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61\u201376","journal-title":"Genet Med"},{"issue":"12","key":"3392_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","volume":"121","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Taher AT, Cappellini MD, Sankaran VG (2013) Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia. Blood 121(12):2199\u20132212","journal-title":"Blood"},{"issue":"1s","key":"3392_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4081\/thal.2013.s1.e39","volume":"3","author":"M Karimi","year":"2013","unstructured":"Karimi M, Cohan N (2013) Induction of HBF. Thalassemia Reports 3(1s):39","journal-title":"Thalassemia Reports"},{"issue":"5","key":"3392_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2141.2010.08486.x","volume":"152","author":"AT Taher","year":"2011","unstructured":"Taher AT, Musallam KM, Cappellini MD, Weatherall DJ (2011) Optimal management of \u03b2 thalassaemia intermedia. Br J Haematol 152(5):512\u2013523","journal-title":"Br J Haematol"},{"issue":"1","key":"3392_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.2010.05593.x","volume":"1202","author":"SP Perrine","year":"2010","unstructured":"Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S (2010) Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci 1202(1):158\u2013164","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"3392_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/01.mph.0000174386.13109.28","volume":"27","author":"M Karimi","year":"2005","unstructured":"Karimi M, Darzi H, Yavarian M (2005) Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol 27(7):380\u2013385","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"3392_CR11","first-page":"47","volume":"7","author":"AD Fard","year":"2013","unstructured":"Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K (2013) Evaluation of novel fetal hemoglobin inducer drugs in treatment of \u03b2-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 7(3):47\u201354","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"8","key":"3392_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/17425247.2014.919253","volume":"11","author":"R Pangeni","year":"2014","unstructured":"Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S (2014) Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 11(8):1285\u20131298","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"3392_CR13","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1039\/C7FO01300K","volume":"8","author":"A Rauf","year":"2017","unstructured":"Rauf A, Imran M, Suleria HAR, Ahmad B, Peters DG, Mubarak MS (2017) A comprehensive review of the health perspectives of resveratrol. Food Funct 8(12):4284\u20134305","journal-title":"Food Funct"},{"issue":"2","key":"3392_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1046\/j.1365-2141.2001.02746.x","volume":"113","author":"CM Rodrigue","year":"2001","unstructured":"Rodrigue CM, Arous N, Bachir D, Smith-Ravin J, Romeo PH, Galacteros F, Garel MC (2001) Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br J Haematol 113(2):500\u2013507","journal-title":"Br J Haematol"},{"issue":"6","key":"3392_CR15","first-page":"974","volume":"29","author":"E Fibach","year":"2012","unstructured":"Fibach E, Prus E, Bianchi N, Zuccato C, Breveglieri G, Salvatori F, Finotti A, Lipucci M, Paola D, Brognara E (2012) Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and \u03b2-thalassemia patients. Int J Mol Med 29(6):974\u2013982","journal-title":"Int J Mol Med"},{"issue":"2","key":"3392_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/092986707779313318","volume":"14","author":"R Gambari","year":"2007","unstructured":"Gambari R, Fibach E (2007) Medicinal chemistry of fetal hemoglobin inducers for treatment of \u03b2-thalassemia. Curr Med Chem 14(2):199\u2013212","journal-title":"Curr Med Chem"},{"issue":"6","key":"3392_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00277-008-0637-y","volume":"88","author":"U Testa","year":"2009","unstructured":"Testa U (2009) Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 88(6):505\u2013528","journal-title":"Ann Hematol"},{"issue":"1","key":"3392_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","volume":"1215","author":"T Walle","year":"2011","unstructured":"Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215(1):9\u201315","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"3392_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2221-1691(13)60060-X","volume":"3","author":"K Kesarwani","year":"2013","unstructured":"Kesarwani K, Gupta R (2013) Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed 3(4):253\u2013266","journal-title":"Asian Pac J Trop Biomed"},{"key":"3392_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/637953","volume":"2012","author":"GB Dudhatra","year":"2012","unstructured":"Dudhatra GB, Mody SK, Awale MM, Patel HB, Modi CM, Kumar A, Kamani DR, Chauhan BN (2012) A comprehensive review on pharmacotherapeutics of herbal bioenhancers. Sci World J 2012:1\u201333","journal-title":"Sci World J"},{"issue":"8","key":"3392_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/mnfr.201100117","volume":"55","author":"JJ Johnson","year":"2011","unstructured":"Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, Ahmad N (2011) Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res 55(8):1169\u20131176","journal-title":"Mol Nutr Food Res"},{"issue":"11","key":"3392_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003464","volume":"3","author":"A Re Del","year":"2013","unstructured":"Del Re A, Maisel NC, Blodgett JC, Finney JW (2013) Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open 3(11):e003464","journal-title":"BMJ Open"},{"issue":"13","key":"3392_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMct0708272","volume":"358","author":"OS Platt","year":"2008","unstructured":"Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. New Engl J Med 358(13):1362\u20131369","journal-title":"New Engl J Med"},{"issue":"3","key":"3392_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1600-0609.2008.01192.x","volume":"82","author":"M Karimi","year":"2009","unstructured":"Karimi M, Borzouee M, Mehrabani A, Cohan N (2009) Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol 82(3):213\u2013218","journal-title":"Eur J Haematol"},{"issue":"3","key":"3392_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-2141.1995.tb05584.x","volume":"90","author":"YT Zeng","year":"1995","unstructured":"Zeng YT, Huang SZ, Ren ZR, zh L, Zeng FY, Schechter AN, Rodgers GP (1995) Hydroxyurea therapy in \u03b2-thalassaemia intermedia: improvement in haematological parameters due to enhanced \u03b2-globin synthesis. Br J Haematol 90(3):557\u2013563","journal-title":"Br J Haematol"},{"issue":"1","key":"3392_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1749-6632.1998.tb10469.x","volume":"850","author":"D Loukopoulos","year":"1998","unstructured":"Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N (1998) Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 850(1):120\u2013128","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"3392_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0022-3476(05)83304-9","volume":"125","author":"FM Hajjar","year":"1994","unstructured":"Hajjar FM, Pearson HA (1994) Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr 125(3):490\u2013492","journal-title":"J Pediatr"},{"issue":"6","key":"3392_CR28","doi-asserted-by":"publisher","first-page":"e18028","DOI":"10.5812\/ircmj.18028","volume":"16","author":"MR Bordbar","year":"2014","unstructured":"Bordbar MR, Silavizadeh S, Haghpanah S, Kamfiroozi R, Bardestani M, Karimi M (2014) Hydroxyurea treatment in transfusion-dependent \u03b2-thalassemia patients. Iran Red Crescent Med J 16(6):e18028","journal-title":"Iran Red Crescent Med J"},{"issue":"1","key":"3392_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1749-6632.2010.05853.x","volume":"1215","author":"KR Patel","year":"2011","unstructured":"Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215(1):161\u2013169","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3392_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.12205","volume":"1290","author":"A Gescher","year":"2013","unstructured":"Gescher A, Steward WP, Brown K (2013) Resveratrol in the management of human cancer: how strong is the clinical evidence? Ann N Y Acad Sci 1290(1):12\u201320","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"3392_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ghir.2004.01.005","volume":"14","author":"YH Ibrahim","year":"2004","unstructured":"Ibrahim YH, Yee D (2004) Insulin-like growth factor-I and cancer risk. Growth Hormon IGF Res 14(4):261\u2013269","journal-title":"Growth Hormon IGF Res"},{"issue":"3","key":"3392_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1046\/j.1440-1711.1999.00822.x","volume":"77","author":"AJ Butt","year":"1999","unstructured":"Butt AJ, Firth SM, Baxter RC (1999) The IGF axis and programmed cell death. Immunol Cell Biol 77(3):256\u2013262","journal-title":"Immunol Cell Biol"},{"issue":"9","key":"3392_CR33","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/1940-6207.CAPR-09-0155","volume":"3","author":"HS Chow","year":"2010","unstructured":"Chow HS, Garland LL, Hsu C-H, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS (2010) Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 3(9):1168\u20131175","journal-title":"Cancer Prev Res"},{"issue":"7","key":"3392_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/11531820-000000000-00000","volume":"49","author":"C Porte la","year":"2010","unstructured":"la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW (2010) Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49(7):449\u2013454","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3392_CR35","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1055-9965.EPI-07-0022","volume":"16","author":"DJ Boocock","year":"2007","unstructured":"Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Prev Biomarkers 16(6):1246\u20131252","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"issue":"22","key":"3392_CR36","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1158\/0008-5472.CAN-10-2364","volume":"70","author":"VA Brown","year":"2010","unstructured":"Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70(22):9003\u20139011","journal-title":"Cancer Res"},{"key":"3392_CR37","volume-title":"American Herbal Products Association\u2019s botanical safety handbook","author":"Z Gardner","year":"2013","unstructured":"Gardner Z, McGuffin M (2013) American Herbal Products Association\u2019s botanical safety handbook, second edn. CRC press, Boca Raton","edition":"second edn"},{"issue":"6","key":"3392_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019881","volume":"6","author":"O Vang","year":"2011","unstructured":"Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin H-Y (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6(6):e19881","journal-title":"PLoS One"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3392-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T09:40:15Z","timestamp":1569145215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3392-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3392-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the local Ethics Committee of Shiraz University of Medical Sciences (approval code 7691, and Ethics Committee code IR.sums.REC.1394.16). Prior to start of the study, details were explained to each patient, and a written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}